Delivery Order SPE2DB24D1006-SPE2DB25FCEYT
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for pharmaceutical supplies, specifically MENQUADFI vial 0.5ML, with a ceiling value of $1,452.88. This delivery order utilizes a firm fixed price contract type and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $47,395.64 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of MENQUADFI VIAL 0.5ML pharmaceutical products. The contract has a completion date of March 8, 2024. Amerisourcebergen Drug Corp is the prime contractor and the award was made through DLA's Troop Support Medical program without any set-aside designation. This delivery order is part of a larger,...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,452.88 by the Defense Logistics Agency (DLA) for MENQUADFI VIAL 0.5ML, a pharmaceutical product. The contract is competitively awarded with no set-aside designation and operates under a firm fixed price structure, with an ultimate completion date of August 4, 2025. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,756.20 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division. The contract, which does not have a set-aside designation, is for the supply of 4564736964 ! MENQUADFI VIAL 0.5ML medical products. This delivery order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. Under this IDC,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of MENQUADFI vial 0.5ML, a meningococcal vaccine product. The contract is valued at $2,179.32 with a firm fixed price structure and an ultimate completion date of July 30, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the pharmaceutical product MENQUADFI VIAL 0.5ML. The contract has a ceiling value of $5,028.10 and a period of performance through February 6, 2023. This award is associated with a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp, which has a potential value of $999,999,999.00 and...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $4,216.30 to AmerisourceBergen Drug Corp on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award represents a pharmaceutical delivery to be...
- The U.S. Defense Logistics Agency (DLA) awarded a $61,256 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply MENQUADFI VIAL 0.5ML pharmaceutical products. This delivery order was placed under Amerisourcebergen's existing indefinite delivery contract with DLA Troop Support Medical to provide pharmaceuticals and medical supplies for military treatment programs and facilities. The contract has a completion date of...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $1,404.96 contract is for the supply of MENQUADFI VIAL 0.5ML, a pharmaceutical product, with a completion date of February 1, 2024. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of MENQUADFI VIAL 0.5ML pharmaceutical products. The $1,053.72 contract has a performance period through February 1, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp, as the prime contractor, will deliver these products to support military treatment programs and...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCEYTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,358.64 to AmerisourceBergen Drug Corp for the supply of MENQUADFI vials (0.5ML) under a firm fixed-price contract type. The award, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive delivery order without set-aside provisions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in the same city. This contract represents a child order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a $999,999,999.00 ceiling value and extends through December 2026. AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting military and veteran healthcare systems. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company has demonstrated capability to meet federal procurement requirements through competitive bidding on both small-value and substantial orders, with contract awards consistently structured as delivery orders with firm fixed pricing across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 8/1/25 |